Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood
A Prospective, Randomized, Controlled Study on Intra-operative Autologous Transfusion With the Sangvia® Blood Salvage System in Spinal Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Glostrup, Denmark
- Clinical Trial Unit, Glostrup Hospital, University of Copenhagen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of informed consent.
- Male and female subjects aged 18 years and over subjected to spinal surgery with an approximate expected bleeding of 800-1500 ml.
- Subjects classified as ASA Physical Status Classification System class P1, P2 or P3 according to the American Society of Anaesthesiology.
Exclusion Criteria:
- Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site).
- Previous enrolment or randomisation of treatment in the present study.
- Participation in another clinical study, that may interfere with the present study.
- Severe non-compliance to protocol as judged by the investigator and/or Astra Tech.
- Haemophilia.
- Hyperkalemia (i.e. values above the normal reference values at study site).
- Symptoms of impaired renal function including creatinine clearance levels (using the Cockcroft-Gault formula) <30 ml/min.
- Malignancy in the area of the operative site.
- Current or expected use of cytotoxic drugs.
- Symptoms of systemic infection or local infection in the operation field.
- Pregnancy.
- Sickle cell anaemia and/or pre-operative Hb concentration <11 g/dl (6,8 mmol/l).
- Use of recombinant erythropoietin (EPO) or fibrin sealant.
- Use of other autologous blood transfusion than with the Sangvia® system (e.g. CellSaver and pre-donation) or other blood saving techniques (e.g. normovolemic hemodilution).
- Hypotensive anesthesia.
- Use of antithrombotic medication within 5 days of surgery (NSAID, Clopidogrel).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Sangvia and retransfusion
|
The Sangvia® Blood Salvage System used to collect blood intra-operatively.
|
|
SHAM_COMPARATOR: Sangvia and no retransfusion
|
The Sangvia® Blood Salvage System used to collect blood intra-operatively.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in Plasma Free Hemoglobin (p-Hb) Concentration
Time Frame: At screening and 24 hours after surgery (surgery takes place 1-7 days after screening)
|
Difference in plasma free hemoglobin (p-Hb) concentration between screening and 24 hours after surgery
|
At screening and 24 hours after surgery (surgery takes place 1-7 days after screening)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma Free Hemoglobin (p-Hb) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic plasma free hemoglobin (p-Hb) concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Hemoglobin Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic hemoglobin concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Potassium Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic potassium concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Creatinine Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic creatinine concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Interleukin-1-alpha (IL-1-α) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic IL-1-α concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Interleukin-6 (IL-6) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic IL-6 concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Interleukin-8 (IL-8) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic IL-8 concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Interleukin-10 (IL-10) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic IL-10 concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Tumor Necrosis Factor Alpha (TNF-α) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic TNF-α concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Interferon Gamma (IFN-γ) Concentration
Time Frame: At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Systemic IFN-γ concentration from screening until 96 hours after surgery.
|
At screening and up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
|
Mean Blood Loss Volume
Time Frame: After surgery (surgery takes place 1-7 days after screening)
|
Estimated blood loss during and after surgery.
|
After surgery (surgery takes place 1-7 days after screening)
|
|
Frequency of Allogenic Blood Transfusion
Time Frame: Up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Up until 96 hours after surgery (surgery takes place 1-7 days after screening)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Rud Lassen, MD, Glostrup Hospital, University of Copenhagen
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- YA-DRA-0006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.